PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Re-evaluating the time of your life

Tel Aviv University researcher investigates the 'subjective time trajectory' in psychological health

2010-10-13
(Press-News.org) In life, we're told, we must take the good with the bad, and how we view these life events determines our well-being and ability to adjust. But according to Prof. Dov Shmotkin of Tel Aviv University's Department of Psychology, you need more than the right attitude to successfully negotiate the vicissitudes of life.

As recently reported in Aging and Mental Health, Prof. Shmotkin's research reveals that people's well-being and their adaptation can be ascertained by their "time trajectory" ― their concept of how they have evolved through their remembered past, currently perceived present, and anticipated future. A close study of how patients compartmentalize their life into these periods can help clinical psychologists treat them more effectively, he says.

From trauma to everyday life

Prof. Shmotkin says that the theory emerged from the study of patients who had experienced traumatic events. "We discovered that overcoming trauma was related to how people organized the memory of their trauma on the larger time continuum of their life course," he explains.

In a study of Holocaust survivors, Prof. Shmotkin separated these survivors into those who considered the "Holocaust as past" and those who conceived of the "Holocaust as present." Those in the "Holocaust as past" category were able to draw an effective line between the present day and the past trauma, thus allowing themselves to move forward. Those in the "Holocaust as present" category considered their traumatic experience as still existing, which indicated a difficulty in containing the trauma within a specific time limit.

But Prof. Shmotkin quickly saw that these coping mechanisms were not exclusive to those who had experienced trauma. Instead, he theorized, these mechanisms are a part of the normal aging process. When young, he explains, our wishes for self improvement and growth lie in an anticipated future. But as we get older, our longer perspective can help or hinder in confronting the present challenges of aging.

A time line to improve patient care

Prof. Shmotkin tested his thesis in collaboration with his former PhD students, Drs. Yuval Palgi and Amit Shrira. They studied participants with an average age of 92 who described their personal time trajectories in terms of their satisfaction with the recent past, the present, and near future.

The best-functioning participants were those whose time trajectory appeared stable rather than "descending," as was expected to occur is very old age, or "ascending," as is normal for youth and adults. Participants at this advanced age also revealed higher well-being when they managed to contrast their present with the suffering they endured in miserable periods of their life. Notably, Holocaust survivors were less able to make this break between the present and the trauma of their past.

This information, says Prof. Shmotkin, is crucial for improving therapeutic care, although it is often overlooked by clinical psychologists. "A person's subjective time frame is key to the formulation of that person's life story and well-being," he explains. Prof. Shmotkin urges psychologists to try to better understand their patients' personal time trajectories, using these as a tool to help patients reconcile their traumatic pasts and the present challenges of aging.

### American Friends of Tel Aviv University (www.aftau.org) supports Israel's leading, most comprehensive and most sought-after center of higher learning. Independently ranked 94th among the world's top universities for the impact of its research, TAU's innovations and discoveries are cited more often by the global scientific community than all but 10 other universities.

Internationally recognized for the scope and groundbreaking nature of its research and scholarship, Tel Aviv University consistently produces work with profound implications for the future.


ELSE PRESS RELEASES FROM THIS DATE:

Sexual issues a major concern for cancer patients taking new targeted drugs

2010-10-13
New drugs that target specific molecular mechanisms of cancer have improved the treatment of cancer patients in recent years, but those benefits may come with a cost to the patient's sex life, researchers have found. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, French researchers reported on one of the few studies to investigate the impact of cancer therapy on the sexual functioning of patients. Dr Yohann Loriot and Dr Thomas Bessede from Institut Gustave Roussy in Villejuif, France and colleagues found that patients taking ...

Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors

2010-10-13
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib, the results of a Phase IIb/III trial show. At the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy, Dr Vincent Miller from Memorial Sloan-Kettering Cancer Center in New York, USA, reported findings from the LUX-Lung 1 trial of afatinib in 585 patients with lung adenocarcinoma whose cancer had progressed after chemotherapy ...

New Phase II study shows first-line promise of lung cancer drug PF-299

2010-10-13
A new-generation lung cancer drug has shown an impressive ability to prevent disease progression when administered as a first-line treatment in patients with advanced disease, investigators reported at the 35th Congress of the European Society for Medical Oncology (ESMO). Preliminary results from an ongoing Phase-II trial of the drug PF299804 (PF-299) showed that close to 85% of patients whose cancers harbor mutated forms of the EGFR gene have remained progression-free for at least nine months, reported Dr Tony Mok from the Chinese University of Hong Kong. While some ...

Pazopanib shows promise in Phase II trial for relapsed/refractory urothelial cancer

2010-10-13
An ongoing Phase-II trial investigating a new, targeted therapy for metastatic urothelial cancer has generated promising early results, Italian researchers reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy. Urothelial cancers affect the tissue lining the inner surfaces of the bladder and other parts of the urinary system. In cases of metastatic disease, median survival is approximately 12-15 months and there is a 10-15% chance of prolonging it by the use of standard chemotherapy regimens, particularly in otherwise healthy ...

Phase III study shows everolimus delays tumor progression in hard-to-treat neuroendocrine tumors

2010-10-13
The results of a large Phase-III clinical trial have shown that the drug everolimus delays tumor progression in patients with a hard-to-treat group of rare cancers that affect particular hormone-producing cells. At the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Marianne Pavel from Charité University in Berlin, Germany reported that everolimus improved progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. Neuroendocrine tumors are slow-growing malignancies that originate from cells of the body's neuroendocrine ...

Selective strategy could lead to new approaches against schizophrenia

2010-10-13
A new class of compounds identified by researchers at Emory University School of Medicine could be developed into drugs for the treatment of schizophrenia. The compounds enhance signaling by molecules in the brain called NMDA receptors, which scientists believe are functioning at low levels in people with schizophrenia. Led by Stephen Traynelis, PhD, professor of pharmacology, a team of Emory researchers sifted through thousands of chemicals and found one, called CIQ, which could selectively enhance the function of certain NMDA receptors without affecting others. The ...

A picture worth a thousand words: New research links visual cues to male sexual memory

2010-10-13
Iowa City, IA—October 11, 2010— A new study published in Applied Cognitive Psychology finds that college-aged men are very likely to remember a woman's initial sexual interest (attraction or rejection), especially when the woman in question is thought to be attractive, is dressed more provocatively, and expresses positive sexual interest. In the study the men were shown full-body photographs of college-aged women who expressed cues of sexual interest or rejection. The participating males represented mixed sexual histories, and a capacity for varying degrees of sexually ...

University of Florida research provides new understanding of bizarre extinct mammal

University of Florida research provides new understanding of bizarre extinct mammal
2010-10-13
GAINESVILLE, Fla. --- University of Florida researchers presenting new fossil evidence of an exceptionally well-preserved 55-million-year-old North American mammal have found it shares a common ancestor with rodents and primates, including humans.The study published today in the online edition of the Zoological Journal of the Linnean Society, describes the cranial anatomy of the extinct mammal, Labidolemur kayi. High resolution CT scans of the specimens allowed researchers to study minute details in the skull, including bone structures smaller than one-tenth of a millimeter. ...

On the trail of the epigenetic code

On the trail of the epigenetic code
2010-10-13
The genetic inherited material DNA was long viewed as the sole bearer of hereditary information. The function of its packaging proteins, the histones, was believed to be exclusively structural. Additional genetic information can be stored, however, and passed on to subsequent generations through chemical changes in the DNA or histones. Scientists from the Max Planck Institute for Biophysical Chemistry in Göttingen have succeeded in creating an experimental system for testing the function of such chemical histone modifications and their influence on the organism. Chemical ...

Smaller and cheaper but 300 times more intense

2010-10-13
More brilliant X-rays, more cost-effective methods for developing new energy sources and advanced manufacturing processes are just some of the benefits which may come from a novel technology, proven at the theoretical level by a consortium of British and European laser scientists. The research, led by scientists at the Science and Technology Facilities Council's Central Laser Facility is published in this week's edition of Nature Physics (October 10 2010). A team of scientists from the Instituto Superior Tecnico in Lisbon, Imperial College London, and the Universities ...

LAST 30 PRESS RELEASES:

Simple consultations in emergency room can help patients manage high blood pressure

Metachromatic Leukodystrophy (MLD) and gene therapy: a game-changing treatment backed by NEJM—Timing Is Everything

Estimating complex immune cell structures by AI tools for survival prediction in advanced melanoma

Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US

2024 Top 100 US Universities announced by the National Academy of Inventors

Female bonobos keep males in check—not with strength, but with solidarity

What happens in the brain when your mind blanks

The oldest ant ever discovered found fossilized in Brazil

Health care cost concerns and hardships for families of children with disabilities

Trends in mental health diagnoses among publicly insured children

Measles may be making a comeback in the US, Stanford Medicine-led research finds

We still have a representation problem for women in physics – and Canada is no exception

Even light exercise could help slow cognitive decline in people at risk of Alzheimer’s

Prostate cancer discovery opens door to more tailored treatments

The potential oncogenic role of serum-derived hsa_circ_101555 as a non-invasive diagnostic/prognostic marker in patients with hepatocellular carcinoma

Use of traditional Chinese medicine in Chinese patients with cancer receiving outpatient care: primary reasons and communication with oncologists

Largest imaging spectro-polarimeter achieves first light at the NSF Daniel K. Inouye solar telescope

The heart of world’s largest solar telescope begins to beat

Society for cardiovascular angiography & interventions scientific sessions 2025 features latest clinical innovations in cardiology care

Tumor microenvironment dynamics: the regulatory influence of long non-coding RNAs

Research update: Plant-based calamari that rivals real seafood in texture

Rethinking stroke risk in patients with atherosclerotic carotid stenosis

New approach makes AI adaptable for computer vision in crop breeding

Moffitt Cancer Center launches new podcast, The ImmunoVerse, hosted by CEO Dr. Patrick Hwu

Evidence blasted into space: Mystery why some meteorites look less shocked solved

Immune system warriors predict the future of autoimmune blood vessel disease

Canadian experts urge protection for children from escalating heat in schools and child care settings

Awkward. Humans are still better than AI at reading the room

No more copy-pasting: DNA base editing for better Lactobacillus strains

AI provides reliable answers with less computational overhead

[Press-News.org] Re-evaluating the time of your life
Tel Aviv University researcher investigates the 'subjective time trajectory' in psychological health